FIG. 1.

Elevated expression of Prx I and Nrf2 in human-lung adenocarcinoma tissues. (A) Relative expression levels of Prx I and PCNA in paired nontumor (N) and tumor (T) tissue samples from seven patients with adenocarcinoma were determined by Western blotting analysis. GAPDH was used as a loading control. The data are presented as the mean±SEM (n=7). ^**p<0.01, ^***p<0.001 compared with paired nontumor tissue samples. (B) Prx I mRNA level in lung cancer tissues was measured by semi-quantitative PCR. The data are representative of at least three different experiments and presented as mean±SEM (n=4). ^***p<0.001 compared with paired nontumor tissue samples. (C) Human lung adenocarcinoma tissue sections were prepared and stained with anti-Prx I antibody. Asterisks indicate tumor regions. (D) Relative expression levels of Nrf2 and Keap1 in five patients with adenocarcinoma were determined by Western blotting analysis. The data are representative of at least three different experiments and presented as mean±SEM (n=14). ^**p<0.01, ^***p<0.001 compared with paired nontumor tissue samples. (E) Nrf2 and Prx I expression in siNrf2-transfected A549 cells. The data are representative of at least three different experiments. Nrf2, nuclear erythroid 2-related factor 2; Prx I, peroxiredoxin I; siNrf2, siRNA for Nrf2. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars